• Eli Lilly has expanded its LillyDirect platform to include Alzheimer’s care, offering tools for early diagnosis, specialist connections, and educational resources.
  • With long wait times for dementia specialists in the U.S., LillyDirect aims to improve early access to Alzheimer’s care.

Eli Lilly has announced a significant expansion of its direct-to-consumer (D2C) healthcare platform, LillyDirect, to include services for Alzheimer’s disease. This development aims to address the growing challenges in diagnosing and treating the condition by offering U.S. users access to both in-person and virtual care options.

The announcement was made on March 27, 2025, and marks a critical step in the company’s efforts to improve early diagnosis and care for Alzheimer’s patients.

Launched in January 2024, LillyDirect initially focused on providing affordable access to treatments for conditions such as diabetes, migraines, and obesity. Over time, it expanded to include sleep apnea following the approval of Eli Lilly’s GLP-1 drug Zepbound. The latest addition of Alzheimer’s services reflects the platform’s growing scope and its aim to reduce barriers to timely diagnosis and treatment.

The Alzheimer’s section of LillyDirect includes tools like Healthgrades, a doctor locator that helps users find specialists who utilize biomarkers for diagnosis, and Synapticure, a provider specializing in neurodegenerative care.

Additionally, the platform offers educational resources through MorethanNormalAging.com, designed for individuals with memory concerns.

The expansion comes at a time when diagnostic delays for Alzheimer’s are a pressing issue. Current wait times to see dementia specialists in the U.S. average 20 months and are projected to exceed one year by 2025. This delay significantly impacts patients’ ability to access timely treatment, particularly in rural and underserved areas.

David Hyman, M.D., Eli Lilly’s Chief Medical Officer, emphasized the importance of early diagnosis:

“By expanding this platform, we hope to help patients identify and access additional independent specialty care capacity, which can coordinate with a patient’s existing care team.”

Unlike other conditions supported by LillyDirect, the Alzheimer’s section does not include mail-order pharmacy options for medications like Kisunla, Eli Lilly’s FDA-approved treatment for early symptomatic Alzheimer’s.

Instead, the focus is on connecting patients with independent providers and offering educational resources.

Kisunla has shown promise in clinical trials, slowing cognitive decline by up to 35% in early-stage patients and reducing amyloid plaques significantly over an 18-month period. However, barriers such as high costs—approximately $32,000 annually—and limited specialist availability remain challenges.

Eli Lilly is not alone in leveraging D2C platforms to address healthcare gaps. Competitors like Pfizer and Novo Nordisk have also launched similar initiatives targeting various conditions.

However, LillyDirect's focus on Alzheimer's highlights the company’s commitment to tackling one of the most challenging fields in healthcare.

Alzheimer’s Disease: A Growing Crisis

Alzheimer’s affects nearly 7 million Americans today and is expected to impact over 13 million by 2060 due to an aging population. The disease progresses rapidly; approximately 3,000 Americans transition from mild to moderate or severe stages daily. Addressing these challenges requires innovative solutions like those offered by LillyDirect.

While analysts have praised the platform's potential to improve access to care, they note that significant systemic barriers remain. For example, Citi analysts highlighted that “the onus remains on patients to take the first step,” reflecting broader issues in patient engagement and healthcare accessibility.

Eli Lilly's expansion of LillyDirect represents a meaningful effort to bridge gaps in Alzheimer's care by focusing on education, early diagnosis, and streamlined access to specialists. However, systemic challenges such as specialist shortages and high treatment costs must also be addressed to fully realize its potential.

Edited by Harshajit Sarmah